Clinical features of polycythemia vera and essential thrombocythemia in Japan

Retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group

Kazuo Dan, Takashi Yamada, Yukihiko Kimura, Noriko Usui, Shinichiro Okamoto, Takashi Sugihara, Kazue Takai, Michihiko Masuda, Mayumi Mori

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We conducted the first nationwide survey to clarify the clinical features, treatment methods, and prognoses for polycythemia vera (PV) and essential thrombocythemia (ET). A 1-page questionnaire was mailed to members of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Surveys on 647 patients (PV, 266 patients; ET, 381 patients) were returned and analyzed. Thrombotic events at diagnosis and during follow-up occurred at rates of 15.4% and 8.5%, respectively, in PV cases and 17.6% and 8.7% in ET cases. Splenomegaly was observed in only 28.8% of PV patients and 10.8% of ET patients. The leukocyte alkaline phosphatase score was elevated in only 46.2% of PV patients. The incidences of abnormal karyotypes were less than 10% in both PV and ET cases. The rates of transformation to myelofibrosis were 2.6% in both PV and ET cases, and acute leukemia was noted in 1.1% of PV patients and 2.9% of ET patients. Prognostic factors were thrombotic history for PV and thrombotic history and age (≥60 years) for ET. The present study clearly demonstrated clinical differences between Japanese and Western patients for PV and ET Concerning the treatment of PV and ET, the study revealed considerable variation among Japanese hematologists. These results suggest the necessity of developing treatment guidelines according to risk stratification that are suitable for Japanese PV and ET patients.

Original languageEnglish
Pages (from-to)443-449
Number of pages7
JournalInternational Journal of Hematology
Volume83
Issue number5
DOIs
Publication statusPublished - 2006 Jun

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Lymphoma
Japan
Leukemia
Surveys and Questionnaires
History
Abnormal Karyotype
Primary Myelofibrosis
Splenomegaly
Alkaline Phosphatase
Leukocytes

Keywords

  • Clinical features
  • Essential thrombocythemia
  • Nationwide survey
  • Polycythemia vera
  • Retrospective analysis

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical features of polycythemia vera and essential thrombocythemia in Japan : Retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. / Dan, Kazuo; Yamada, Takashi; Kimura, Yukihiko; Usui, Noriko; Okamoto, Shinichiro; Sugihara, Takashi; Takai, Kazue; Masuda, Michihiko; Mori, Mayumi.

In: International Journal of Hematology, Vol. 83, No. 5, 06.2006, p. 443-449.

Research output: Contribution to journalArticle

Dan, Kazuo ; Yamada, Takashi ; Kimura, Yukihiko ; Usui, Noriko ; Okamoto, Shinichiro ; Sugihara, Takashi ; Takai, Kazue ; Masuda, Michihiko ; Mori, Mayumi. / Clinical features of polycythemia vera and essential thrombocythemia in Japan : Retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. In: International Journal of Hematology. 2006 ; Vol. 83, No. 5. pp. 443-449.
@article{61c2d2d518414f9fa3ac229384fdaef1,
title = "Clinical features of polycythemia vera and essential thrombocythemia in Japan: Retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group",
abstract = "We conducted the first nationwide survey to clarify the clinical features, treatment methods, and prognoses for polycythemia vera (PV) and essential thrombocythemia (ET). A 1-page questionnaire was mailed to members of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Surveys on 647 patients (PV, 266 patients; ET, 381 patients) were returned and analyzed. Thrombotic events at diagnosis and during follow-up occurred at rates of 15.4{\%} and 8.5{\%}, respectively, in PV cases and 17.6{\%} and 8.7{\%} in ET cases. Splenomegaly was observed in only 28.8{\%} of PV patients and 10.8{\%} of ET patients. The leukocyte alkaline phosphatase score was elevated in only 46.2{\%} of PV patients. The incidences of abnormal karyotypes were less than 10{\%} in both PV and ET cases. The rates of transformation to myelofibrosis were 2.6{\%} in both PV and ET cases, and acute leukemia was noted in 1.1{\%} of PV patients and 2.9{\%} of ET patients. Prognostic factors were thrombotic history for PV and thrombotic history and age (≥60 years) for ET. The present study clearly demonstrated clinical differences between Japanese and Western patients for PV and ET Concerning the treatment of PV and ET, the study revealed considerable variation among Japanese hematologists. These results suggest the necessity of developing treatment guidelines according to risk stratification that are suitable for Japanese PV and ET patients.",
keywords = "Clinical features, Essential thrombocythemia, Nationwide survey, Polycythemia vera, Retrospective analysis",
author = "Kazuo Dan and Takashi Yamada and Yukihiko Kimura and Noriko Usui and Shinichiro Okamoto and Takashi Sugihara and Kazue Takai and Michihiko Masuda and Mayumi Mori",
year = "2006",
month = "6",
doi = "10.1532/IJH97.06009",
language = "English",
volume = "83",
pages = "443--449",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Clinical features of polycythemia vera and essential thrombocythemia in Japan

T2 - Retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group

AU - Dan, Kazuo

AU - Yamada, Takashi

AU - Kimura, Yukihiko

AU - Usui, Noriko

AU - Okamoto, Shinichiro

AU - Sugihara, Takashi

AU - Takai, Kazue

AU - Masuda, Michihiko

AU - Mori, Mayumi

PY - 2006/6

Y1 - 2006/6

N2 - We conducted the first nationwide survey to clarify the clinical features, treatment methods, and prognoses for polycythemia vera (PV) and essential thrombocythemia (ET). A 1-page questionnaire was mailed to members of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Surveys on 647 patients (PV, 266 patients; ET, 381 patients) were returned and analyzed. Thrombotic events at diagnosis and during follow-up occurred at rates of 15.4% and 8.5%, respectively, in PV cases and 17.6% and 8.7% in ET cases. Splenomegaly was observed in only 28.8% of PV patients and 10.8% of ET patients. The leukocyte alkaline phosphatase score was elevated in only 46.2% of PV patients. The incidences of abnormal karyotypes were less than 10% in both PV and ET cases. The rates of transformation to myelofibrosis were 2.6% in both PV and ET cases, and acute leukemia was noted in 1.1% of PV patients and 2.9% of ET patients. Prognostic factors were thrombotic history for PV and thrombotic history and age (≥60 years) for ET. The present study clearly demonstrated clinical differences between Japanese and Western patients for PV and ET Concerning the treatment of PV and ET, the study revealed considerable variation among Japanese hematologists. These results suggest the necessity of developing treatment guidelines according to risk stratification that are suitable for Japanese PV and ET patients.

AB - We conducted the first nationwide survey to clarify the clinical features, treatment methods, and prognoses for polycythemia vera (PV) and essential thrombocythemia (ET). A 1-page questionnaire was mailed to members of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Surveys on 647 patients (PV, 266 patients; ET, 381 patients) were returned and analyzed. Thrombotic events at diagnosis and during follow-up occurred at rates of 15.4% and 8.5%, respectively, in PV cases and 17.6% and 8.7% in ET cases. Splenomegaly was observed in only 28.8% of PV patients and 10.8% of ET patients. The leukocyte alkaline phosphatase score was elevated in only 46.2% of PV patients. The incidences of abnormal karyotypes were less than 10% in both PV and ET cases. The rates of transformation to myelofibrosis were 2.6% in both PV and ET cases, and acute leukemia was noted in 1.1% of PV patients and 2.9% of ET patients. Prognostic factors were thrombotic history for PV and thrombotic history and age (≥60 years) for ET. The present study clearly demonstrated clinical differences between Japanese and Western patients for PV and ET Concerning the treatment of PV and ET, the study revealed considerable variation among Japanese hematologists. These results suggest the necessity of developing treatment guidelines according to risk stratification that are suitable for Japanese PV and ET patients.

KW - Clinical features

KW - Essential thrombocythemia

KW - Nationwide survey

KW - Polycythemia vera

KW - Retrospective analysis

UR - http://www.scopus.com/inward/record.url?scp=33751032902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751032902&partnerID=8YFLogxK

U2 - 10.1532/IJH97.06009

DO - 10.1532/IJH97.06009

M3 - Article

VL - 83

SP - 443

EP - 449

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -